1. Market Research
  2. > Business Services
  3. > Research and Development Market Trends
  4. > Nuvilex, Inc. - Product Pipeline Review - 2014

Nuvilex, Inc. - Product Pipeline Review - 2014

  • November 2014
  • -
  • Global Markets Direct
  • -
  • 21 pages

Nuvilex, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘Nuvilex, Inc. - Product Pipeline Review - 2014’, provides an overview of the Nuvilex, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Nuvilex, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Nuvilex, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Nuvilex, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Nuvilex, Inc.’s pipeline products

Reasons to buy

- Evaluate Nuvilex, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Nuvilex, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Nuvilex, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Nuvilex, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Nuvilex, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Nuvilex, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Nuvilex, Inc. - Product Pipeline Review - 2014
Table of Contents

Nuvilex, Inc. Snapshot 4
Nuvilex, Inc. Overview 4
Key Information 4
Key Facts 4
Nuvilex, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Nuvilex, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Nuvilex, Inc. - Pipeline Products Glance 9
Nuvilex, Inc. - Early Stage Pipeline Products 9
Preclinical Products/Combination Treatment Modalities 9
Nuvilex, Inc. - Drug Profiles 10
Alternia 10
Product Description 10
Mechanism of Action 10
RandD Progress 10
Cell Therapy for Diabetes 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
Small Molecule 1 to Inhibit CB1 for Cancer 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
Small Molecule 2 to Inhibit CB1 for Cancer 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
Nuvilex, Inc. - Pipeline Analysis 14
Nuvilex, Inc. - Pipeline Products by Target 14
Nuvilex, Inc. - Pipeline Products by Molecule Type 15
Nuvilex, Inc. - Pipeline Products by Mechanism of Action 16
Nuvilex, Inc. - Recent Pipeline Updates 17
Nuvilex, Inc. - Dormant Projects 18
Nuvilex, Inc. - Locations And Subsidiaries 19
Head Office 19
Other Locations and Subsidiaries 19
Appendix 20
Methodology 20
Coverage 20
Secondary Research 20
Primary Research 20
Expert Panel Validation 20
Contact Us 21
Disclaimer 21

List of Tables

Nuvilex, Inc., Key Information 4
Nuvilex, Inc., Key Facts 4
Nuvilex, Inc. - Pipeline by Indication, 2014 6
Nuvilex, Inc. - Pipeline by Stage of Development, 2014 7
Nuvilex, Inc. - Monotherapy Products in Pipeline, 2014 8
Nuvilex, Inc. - Preclinical, 2014 9
Nuvilex, Inc. - Pipeline by Target, 2014 14
Nuvilex, Inc. - Pipeline by Molecule Type, 2014 15
Nuvilex, Inc. - Pipeline Products by Mechanism of Action, 2014 16
Nuvilex, Inc. - Recent Pipeline Updates, 2014 17
Nuvilex, Inc. - Dormant Developmental Projects,2014 18
Nuvilex, Inc., Subsidiaries 19

List of Figures

Nuvilex, Inc. - Pipeline by Top 10 Indication, 2014 6
Nuvilex, Inc. - Pipeline by Top 10 Molecule Type, 2014 15

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016’, provides in depth analysis on Integrin Alpha 7 (ITGA7) ...

Pulmonary Fibrosis - Pipeline Review, H2 2016

Pulmonary Fibrosis - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Pulmonary Fibrosis - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Pulmonary Fibrosis - Pipeline Review, H2 2016’, provides an overview of the Pulmonary Fibrosis pipeline landscape. ...

Cognitive Impairment - Pipeline Review, H2 2016

Cognitive Impairment - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Cognitive Impairment - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cognitive Impairment - Pipeline Review, H2 2016’, provides an overview of the Cognitive Impairment pipeline landscape. ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.